NO329848B1 - Anvendelse av rekonstituert HDL - Google Patents
Anvendelse av rekonstituert HDL Download PDFInfo
- Publication number
- NO329848B1 NO329848B1 NO20030137A NO20030137A NO329848B1 NO 329848 B1 NO329848 B1 NO 329848B1 NO 20030137 A NO20030137 A NO 20030137A NO 20030137 A NO20030137 A NO 20030137A NO 329848 B1 NO329848 B1 NO 329848B1
- Authority
- NO
- Norway
- Prior art keywords
- rhdl
- use according
- treatment
- infusion
- apolipoprotein
- Prior art date
Links
- 230000001154 acute effect Effects 0.000 claims abstract description 17
- 208000007814 Unstable Angina Diseases 0.000 claims abstract description 12
- 230000008753 endothelial function Effects 0.000 claims abstract description 11
- 238000001802 infusion Methods 0.000 claims description 29
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 15
- 208000010125 myocardial infarction Diseases 0.000 claims description 8
- 235000012000 cholesterol Nutrition 0.000 claims description 7
- 230000006872 improvement Effects 0.000 claims description 7
- 238000001990 intravenous administration Methods 0.000 claims description 6
- 150000002632 lipids Chemical class 0.000 claims description 6
- 108010071619 Apolipoproteins Proteins 0.000 claims description 5
- 102000007592 Apolipoproteins Human genes 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 238000011321 prophylaxis Methods 0.000 claims description 5
- 208000019553 vascular disease Diseases 0.000 claims description 5
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims description 4
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 2
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 abstract description 5
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract description 2
- 210000003038 endothelium Anatomy 0.000 description 20
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 15
- 229960004373 acetylcholine Drugs 0.000 description 15
- 230000017531 blood circulation Effects 0.000 description 15
- 210000000245 forearm Anatomy 0.000 description 15
- 108010010234 HDL Lipoproteins Proteins 0.000 description 14
- 102000015779 HDL Lipoproteins Human genes 0.000 description 14
- 230000024883 vasodilation Effects 0.000 description 14
- 230000000260 hypercholesteremic effect Effects 0.000 description 13
- 229940083618 sodium nitroprusside Drugs 0.000 description 12
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 11
- 238000000034 method Methods 0.000 description 9
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 7
- NTNWOCRCBQPEKQ-UHFFFAOYSA-N NG-mono-methyl-L-arginine Natural products CN=C(N)NCCCC(N)C(O)=O NTNWOCRCBQPEKQ-UHFFFAOYSA-N 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000001361 intraarterial administration Methods 0.000 description 7
- 102000009027 Albumins Human genes 0.000 description 6
- 108010088751 Albumins Proteins 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 5
- 201000001320 Atherosclerosis Diseases 0.000 description 5
- 238000008214 LDL Cholesterol Methods 0.000 description 5
- 206010047141 Vasodilatation Diseases 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000007257 malfunction Effects 0.000 description 3
- 238000002600 positron emission tomography Methods 0.000 description 3
- 230000004141 reverse cholesterol transport Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000000304 vasodilatating effect Effects 0.000 description 3
- 229940124638 COX inhibitor Drugs 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010058990 Venous occlusion Diseases 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000002823 nitrates Chemical class 0.000 description 2
- 238000011458 pharmacological treatment Methods 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- CZMRCDWAGMRECN-UHFFFAOYSA-N 2-{[3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 1
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 102100033902 Endothelin-1 Human genes 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- 108010056764 Eptifibatide Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- JUGOREOARAHOCO-UHFFFAOYSA-M acetylcholine chloride Chemical compound [Cl-].CC(=O)OCC[N+](C)(C)C JUGOREOARAHOCO-UHFFFAOYSA-M 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000011366 aggressive therapy Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000002302 brachial artery Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- -1 cholesterol Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000005796 circulatory shock Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- CZKPOZZJODAYPZ-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CNC2=CC=CC=C12 CZKPOZZJODAYPZ-LROMGURASA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000000544 hyperemic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940056984 integrilin Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 230000008604 lipoprotein metabolism Effects 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940008255 miochol Drugs 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 230000008692 neointimal formation Effects 0.000 description 1
- 229960002460 nitroprusside Drugs 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- OVUHNAFKIACGBB-UHFFFAOYSA-N sodium 2-acetyloxyethyl(trimethyl)azanium Chemical compound [Na+].CC(=O)OCC[N+](C)(C)C OVUHNAFKIACGBB-UHFFFAOYSA-N 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229960003425 tirofiban Drugs 0.000 description 1
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Pretreatment Of Seeds And Plants (AREA)
- External Artificial Organs (AREA)
- Flanged Joints, Insulating Joints, And Other Joints (AREA)
- Supports For Pipes And Cables (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10035352A DE10035352A1 (de) | 2000-07-20 | 2000-07-20 | Verfahren zur Behandlung von instabiler Angina pectoris |
| PCT/EP2001/008425 WO2002007753A2 (de) | 2000-07-20 | 2001-07-20 | Verfahren zur behandlung von instabiler angina pectoris |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20030137D0 NO20030137D0 (no) | 2003-01-10 |
| NO20030137L NO20030137L (no) | 2003-01-10 |
| NO329848B1 true NO329848B1 (no) | 2011-01-10 |
Family
ID=7649620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20030137A NO329848B1 (no) | 2000-07-20 | 2003-01-10 | Anvendelse av rekonstituert HDL |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7053049B2 (pl) |
| EP (1) | EP1303294B1 (pl) |
| JP (1) | JP4928047B2 (pl) |
| KR (2) | KR20070108955A (pl) |
| AT (1) | ATE333887T1 (pl) |
| AU (2) | AU8200401A (pl) |
| CA (1) | CA2418238C (pl) |
| DE (2) | DE10035352A1 (pl) |
| DK (1) | DK1303294T3 (pl) |
| ES (1) | ES2266234T3 (pl) |
| HU (1) | HU230151B1 (pl) |
| IL (2) | IL154006A0 (pl) |
| NO (1) | NO329848B1 (pl) |
| NZ (1) | NZ523784A (pl) |
| PL (1) | PL204406B1 (pl) |
| WO (1) | WO2002007753A2 (pl) |
| ZA (1) | ZA200300509B (pl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007000924A1 (ja) * | 2005-06-28 | 2007-01-04 | Osaka University | プログラニュリン活性を抑制または促進する物質を含む医薬組成物、およびプログラニュリン活性を抑制または促進する物質のスクリーニング方法 |
| US7956035B2 (en) * | 2007-03-01 | 2011-06-07 | Csl Limited | Treatment of endothelial dysfunction in diabetic patients |
| US20090110739A1 (en) * | 2007-05-15 | 2009-04-30 | University Of North Texas Health Science Center At Forth Worth | Targeted cancer chemotherapy using synthetic nanoparticles |
| CA2780482A1 (en) | 2008-11-17 | 2010-05-10 | Anil K. Sood | Hdl particles for delivery of nucleic acids |
| CN104487253B (zh) | 2012-09-25 | 2016-05-25 | 惠普发展公司，有限责任合伙企业 | 液滴检测 |
| ITMI20131300A1 (it) * | 2013-08-01 | 2015-02-02 | Nobil Bio Ricerche Srl | Composizione per il riempimento di difetti ossei e parodontali |
| US9763892B2 (en) | 2015-06-01 | 2017-09-19 | Autotelic Llc | Immediate release phospholipid-coated therapeutic agent nanoparticles and related methods |
| GB2603950A (en) | 2021-02-22 | 2022-08-24 | Reckitt & Colman Overseas Hygiene Home Ltd | Effervescent germicidal compositions |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5128318A (en) * | 1987-05-20 | 1992-07-07 | The Rogosin Institute | Reconstituted HDL particles and uses thereof |
| CA1335077C (en) * | 1988-02-08 | 1995-04-04 | Henri Isliker | Process for the manufacture of apolipoproteins from human blood plasma or serum |
| EP0543417A1 (en) * | 1991-11-22 | 1993-05-26 | Lipogenics, Incorporated | Tocotrienols and tocotrienol-like compounds and methods for their use |
| US5652339A (en) * | 1993-12-31 | 1997-07-29 | Rotkreuzstiftung Zentrallaboratorium | Method of producing reconstituted lipoproteins |
| JPH10218861A (ja) * | 1997-02-04 | 1998-08-18 | Yamanouchi Pharmaceut Co Ltd | 新規なフェネタノール誘導体又はその塩 |
| US6140342A (en) * | 1998-09-17 | 2000-10-31 | Pfizer Inc. | Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines |
| GB9919713D0 (en) * | 1999-08-19 | 1999-10-20 | Queen Mary & Westfield College | New medical use of high density lipoprotein |
| AUPQ429399A0 (en) * | 1999-11-26 | 1999-12-23 | Heart Research Institute, The | Oxidized apolipoproteins and methods of use |
| AU777788B2 (en) * | 1999-11-26 | 2004-10-28 | Heart Research Institute Limited, The | Oxidized apolipoproteins and methods of use |
-
2000
- 2000-07-20 DE DE10035352A patent/DE10035352A1/de not_active Ceased
-
2001
- 2001-07-20 EP EP01960527A patent/EP1303294B1/de not_active Expired - Lifetime
- 2001-07-20 NZ NZ523784A patent/NZ523784A/en not_active IP Right Cessation
- 2001-07-20 IL IL15400601A patent/IL154006A0/xx unknown
- 2001-07-20 JP JP2002513486A patent/JP4928047B2/ja not_active Expired - Fee Related
- 2001-07-20 DK DK01960527T patent/DK1303294T3/da active
- 2001-07-20 AU AU8200401A patent/AU8200401A/xx active Pending
- 2001-07-20 HU HU0300730A patent/HU230151B1/hu not_active IP Right Cessation
- 2001-07-20 AT AT01960527T patent/ATE333887T1/de active
- 2001-07-20 AU AU2001282004A patent/AU2001282004B2/en not_active Ceased
- 2001-07-20 CA CA2418238A patent/CA2418238C/en not_active Expired - Fee Related
- 2001-07-20 KR KR1020077025016A patent/KR20070108955A/ko not_active Application Discontinuation
- 2001-07-20 WO PCT/EP2001/008425 patent/WO2002007753A2/de active IP Right Grant
- 2001-07-20 ES ES01960527T patent/ES2266234T3/es not_active Expired - Lifetime
- 2001-07-20 KR KR1020037000809A patent/KR100864079B1/ko not_active IP Right Cessation
- 2001-07-20 US US10/333,212 patent/US7053049B2/en not_active Expired - Lifetime
- 2001-07-20 DE DE50110552T patent/DE50110552D1/de not_active Expired - Lifetime
- 2001-07-20 PL PL366395A patent/PL204406B1/pl unknown
-
2003
- 2003-01-10 NO NO20030137A patent/NO329848B1/no not_active IP Right Cessation
- 2003-01-16 IL IL154006A patent/IL154006A/en not_active IP Right Cessation
- 2003-01-20 ZA ZA200300509A patent/ZA200300509B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2418238A1 (en) | 2003-01-16 |
| JP2004504355A (ja) | 2004-02-12 |
| IL154006A0 (en) | 2003-07-31 |
| ZA200300509B (en) | 2004-02-17 |
| NO20030137D0 (no) | 2003-01-10 |
| HU230151B1 (hu) | 2015-09-28 |
| NO20030137L (no) | 2003-01-10 |
| JP4928047B2 (ja) | 2012-05-09 |
| EP1303294A2 (de) | 2003-04-23 |
| DE10035352A1 (de) | 2002-01-31 |
| CA2418238C (en) | 2012-06-05 |
| WO2002007753A3 (de) | 2003-02-13 |
| KR100864079B1 (ko) | 2008-10-16 |
| KR20070108955A (ko) | 2007-11-13 |
| AU2001282004B2 (en) | 2006-02-02 |
| EP1303294B1 (de) | 2006-07-26 |
| PL366395A1 (pl) | 2005-01-24 |
| HUP0300730A2 (hu) | 2003-12-29 |
| WO2002007753A2 (de) | 2002-01-31 |
| DK1303294T3 (da) | 2006-10-30 |
| DE50110552D1 (de) | 2006-09-07 |
| PL204406B1 (pl) | 2010-01-29 |
| IL154006A (en) | 2010-05-31 |
| US7053049B2 (en) | 2006-05-30 |
| ES2266234T3 (es) | 2007-03-01 |
| US20040014654A1 (en) | 2004-01-22 |
| NZ523784A (en) | 2004-06-25 |
| HUP0300730A3 (en) | 2010-07-28 |
| AU8200401A (en) | 2002-02-05 |
| ATE333887T1 (de) | 2006-08-15 |
| KR20030026980A (ko) | 2003-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cardillo et al. | Interactions between nitric oxide and endothelin in the regulation of vascular tone of human resistance vessels in vivo | |
| Oudegeest-Sander et al. | The effect of an advanced glycation end-product crosslink breaker and exercise training on vascular function in older individuals: a randomized factorial design trial | |
| EP2749281B1 (en) | Prophylactic and/or therapeutic agent for cardiovascular complications of diabetes | |
| Zhang et al. | Cardioprotective effects of oxymatrine on isoproterenol-induced heart failure via regulation of DDAH/ADMA metabolism pathway in rats | |
| Itoh et al. | The therapeutic effect of lipo PGE1 on diabetic neuropathy-changes in endothelin and various angiopathic factors | |
| Novo et al. | Prevalence of risk factors in patients with peripheral arterial disease | |
| Bahia et al. | Adiponectin is associated with improvement of endothelial function after rosiglitazone treatment in non-diabetic individuals with metabolic syndrome | |
| CN110167538A (zh) | 用于治疗心血管疾病的方法 | |
| NO329848B1 (no) | Anvendelse av rekonstituert HDL | |
| US20180140579A1 (en) | Sacubitril and valsartan for treating metabolic disease | |
| Ono et al. | Telmisartan decreases plasma levels of asymmetrical dimethyl-L-arginine and improves lipid and glucose metabolism and vascular function | |
| US11752122B2 (en) | N-acetylcysteine attenuates aortic stenosis progression by inhibiting shear-mediated TGF-beta activation and signaling | |
| Jasim et al. | Orexin A hormone and its relation to Coronary heart diseases | |
| KR20210013543A (ko) | 내피 세포 기능장애를 조절하기 위한 rps2 펩타이드의 용도 | |
| Xu et al. | Ang II enhances atrial fibroblast autophagy and promotes atrial remodeling through the AT1-ERK-mTOR signaling pathway | |
| Gasic et al. | Effects of ACE inhibition with cilazapril on splanchnic and systemic haemodynamics in man. | |
| US20230355561A1 (en) | N-acetylcysteine attenuates aortic stenosis progression by inhibiting shear-mediated tgf-beta activation and fibrosis | |
| Weiss | Lipid apheresis and rheopheresis for treatment of peripheral arterial disease | |
| CATRINA et al. | A CASE REPORT OF AN AORTIC FLOATING THROMBUS WITH PERIPHERAL EMBOLIZATION IN A 29-YEAR OLD APPARENTLY HEALTHY SUBJECT | |
| Kostov | Cardiovascular risk in patients with type 1 diabetes | |
| JP2022510403A (ja) | 虚血傷害および虚血再灌流傷害の予防および／または治療のための方法および組成物 | |
| Bloomgarden | American Diabetes Association Annual Meeting, 1998: cardiac disease and related topics | |
| Shashurin et al. | EFFECTS OF BETA-BLOCKERS ON PEROXIDE OXIDATION IN ISCHEMIC MODEL OF CONGESTIVE HEART FAILURE IN RATS: PP. 40.306 | |
| Amosova et al. | HEART FAILURE AND LEFT VENTRICULAR SYSTOLIC FUNCTION AFTER ACUTE Q-MYOCARDIAL INFARCTION WITH ANTECEDENT HYPERTENSION: PP. 40.308 | |
| Klimas et al. | EFFECTS OF TESTOSTERONE ON CARDIAC FUNCTION IN PHYSICALLY ACTIVE RATS: PP. 40.307 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |